In 2018 I plan to write a “Critical Issues” series for CEOs, boards, and senior teams. Drawing from current news events and the real, every-day challenges I work on with CEOs, I hope to spark discussion, debate, and action. In addition to my own writing, I’ll share and provide context around important articles from others.
Today I want to highlight a Harvard Business Review article on activist investors -- whether by hedge funds, corporate raiders, or family/private investors. The piece uses data and examples to illustrate the flaws in the model most investors have used for decades to measure shareholder value, and offers a new purpose oriented model. David Pyott, our own CEO from Orange County, who led Allergan through their takeover bid, is interviewed following the article.Read More